Lagevrio
(Molnupiravir)Phase 3Small molecule
Merck & Co.Molnupiravir is an antiviral medication used to treat mild to moderate COVID-19 in adults at high risk of severe illness. It works by interfering with the virus's ability to copy itself in the body.[1] Lagevrio is currently being investigated across 5 indications[3], with its most advanced program in Phase 3.[1]
Lagevrio is one of 182 small molecule programs targeting Viral Disease. It is currently in Phase 3.
5
Indications
24
Total Trials
7
Active Trials
181
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Lagevrio
Merck & Co.Phase 3
Dexilant
TakedaPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Theo-Dur
PfizerPreclinical
Valium
Akero TherapeuticsPreclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Intuniv
PPromius Pharma, LLC
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-1913 trials
Show 10 more trials
Influenza2 trials
Tics1 trial
Dengue1 trial
Adaptive Dengue Antiviral Platform Trial
Not yet recruiting·OOxford University Clinical Research Unit, Vietnam·Phase 2·NCT06551844·500 enrolled
6 more indications
Respiratory Syncytial Virus (RSV)1 trial
Moderate Hepatic Impairment1 trial
Adult1 trial
Renal Impairment1 trial
Cohort Study1 trial
TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
Completed·—··NCT05195060·1,178 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Molnupiravir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company